These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 12666528)

  • 1. [Conn syndrome as cause of stubborn hypertension. Which hypertensives should you screen?].
    Reincke M
    MMW Fortschr Med; 2003 Feb; 145(9):37-40. PubMed ID: 12666528
    [No Abstract]   [Full Text] [Related]  

  • 2. [Secondary forms of hypertension. 5. Hypertension caused by Cushing syndrome and Conn's disease].
    Füessl HS
    MMW Fortschr Med; 2002 Feb; 144(9):42-4. PubMed ID: 11921653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary hyperaldosteronism].
    Plouin PF; Massien-Simon C
    Rev Prat; 1998 Apr; 48(7):749-53. PubMed ID: 11767370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hypertension in a young patient.
    Bakris G
    Hosp Pract (Off Ed); 1993 Oct; 28(10):57-64. PubMed ID: 8408342
    [No Abstract]   [Full Text] [Related]  

  • 5. [Primay hyperaldosteronism--diagnostic and treatment].
    Potthoff SA; Beuschlein F; Vonend O
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2480-4. PubMed ID: 23168980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary hyperaldosteronism].
    Kolyvanos Naumann U; Käser L; Vetter W
    Praxis (Bern 1994); 2003 Nov; 92(48):2039-43. PubMed ID: 14968782
    [No Abstract]   [Full Text] [Related]  

  • 7. [A description of a case of Conn's syndrome (author's transl)].
    Martin PL; Dallocchio M; Fourcade JP; Clémenty J; Coqueran J; Choussat A; Bricaud H
    J Radiol Electrol Med Nucl; 1974 May; 55(5):419-22. PubMed ID: 4408421
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
    Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
    Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modern pharmacological aspects of hyperaldosteronism therapy].
    Quinkler M; Reincke M
    Internist (Berl); 2006 Sep; 47(9):953-9. PubMed ID: 16823578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine.
    Niizuma S; Nakahama H; Kamide K; Fukuchi K; Iwanaga Y; Nakata H; Yoshihara F; Horio T; Nakamura S; Kawano Y
    Clin Exp Hypertens; 2008 Oct; 30(7):640-7. PubMed ID: 18855267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How to unravel hyperaldosteronism in clinical practice].
    van der Giet M
    MMW Fortschr Med; 2014 Oct; 156(17):61-2. PubMed ID: 25417478
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical grand rounds from the University of Alabama Medical Center.
    Hardin JG; Coker AS; Blanton JH
    South Med J; 1969 May; 62(5):599-607. PubMed ID: 4305688
    [No Abstract]   [Full Text] [Related]  

  • 13. [A case of inactive adrenal node that transformed to adenoma with manifestations of primary hyperaldosteronism in a patient with essential hypertension].
    Hatzitolios A; Delivoria C; Karabatsu S; Savopoulos C; Karamuzia M; Tsatidis R; Tataridis A; Kartavenko IM
    Klin Med (Mosk); 2004; 82(9):67-8. PubMed ID: 15540428
    [No Abstract]   [Full Text] [Related]  

  • 14. [Aldosterone antagonists--first choice in resistant hypertension].
    Holzgreve H
    MMW Fortschr Med; 2016 Apr; 158(7):65-6. PubMed ID: 27071591
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.
    Jaffe G; Gray Z; Krishnan G; Stedman M; Zheng Y; Han J; Chertow GM; Leppert JT; Bhalla V
    Hypertension; 2020 Mar; 75(3):650-659. PubMed ID: 32008436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyolysis due to primary hyperaldosteronism.
    Martínez JJ; Oliveira CL; Meneses AL; Rodríguez SA; Corrales PP; López AH; Romero FB
    Endocrinol Nutr; 2009 Oct; 56(8):431-4. PubMed ID: 19959155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of primary aldosteronism with a negative aldosterone-to-renin ratio.
    Liu F; Wang L; Ding Y
    BMC Cardiovasc Disord; 2021 Jul; 21(1):350. PubMed ID: 34294029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test and teach. Surgically correctable hypertension. Conn's syndrome and spironolactone bodies.
    Al Saad KO; Chan NH
    Pathology; 2001 Nov; 33(4):508-10. PubMed ID: 11827421
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary Aldosteronism: Present and Future.
    Funder JW
    Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of spironolactone in the diagnosis and the treatment of hypertension associated with mineralocorticoid excess.
    Beevers DG; Brown JJ; Ferriss JB; Fraser R; Lever AF; Robertson JI
    Am Heart J; 1973 Sep; 86(3):404-14. PubMed ID: 4592546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.